Pay in 4 interest-free payments of $6.16 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial
Sirpiglenastat (Drp-104) induces antitumor efficacy through direct, broad antagonism of glutamine metabolism and stimulation of the innate and adaptive immune systems
In rare cases, the drugs might cause an obstruction in the small bowel, gastroparesis (stomach paralysis), or inflammation of the pancreas (pancreatitis)
If you want help with weight loss, Wegovy is now available in Australia as of August 2024
PBM Decisions Should Prioritize Clinical Evidence, Not Just Bottom Lines : While we understand the need for cost management, formulary decisions for chronic, complex diseases like obesity must be driven by clinical evidence, patient outcomes, and provider expertise
About SELECT SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity) was a randomised, double-blind, parallel-group, placebo-controlled trial designed to evaluate the efficacy of semaglutide 2.4 mg versus placebo as an adjunct to standard of care for reducing the risk of MACE in people with established CVD with overweight or obesity with no prior history of diabetes
US$ 28.43
US$ 24.14
US$ 25.12
US$ 22.68
US$ 22.50
US$ 23.67
US$ 21.77
US$ 25.27
